| abstract |
The present disclosure relates to anti-CD40 antibodies, antigen-binding fragments thereof, and pharmaceutical uses thereof. The heavy chain constant region of the anti-CD40 antibody and its antigen-binding fragment contains a mutation, which makes the anti-CD40 antibody lose its activity of binding to FcγRIII, and at the same time enhances the binding of the anti-CD40 antibody to FcγRIIB, thereby losing the antibody dependence cytotoxicity (ADCC), but enhanced FcγRIIB-mediated antibody cross-linking. Mutations in the heavy chain constant region lead to enhanced activation of CD40, as well as increased antigen presentation by dendritic cells. The anti-CD40 antibodies and antigen-binding fragments thereof of the present disclosure have utility as anticancer drugs for treating CD40-mediated diseases or disorders. |